Expert Opinion on Biological Therapy最新文献_第2页

Personalized psoriatic arthritis therapy: the promise of chromosome conformation signatures. 个体化银屑病关节炎治疗：染色体构象特征的前景。

IF 4 3区医学

Expert Opinion on Biological Therapy Pub Date : 2026-04-01 DOI: 10.1080/14712598.2026.2653784

Patricia Riedlova, Carl S Goodyear, Stefan Siebert

引用次数: 0

Advances in the management of giant cell arteritis-aortitis: biologic therapies and beyond - a narrative review. 巨细胞动脉炎-大动脉炎的治疗进展：生物疗法及其他治疗方法综述。

IF 4 3区医学

Expert Opinion on Biological Therapy Pub Date : 2026-04-01 Epub Date: 2026-03-30 DOI: 10.1080/14712598.2026.2650104

Carmen Secada-Gómez, Adrián Martin-Gutiérrez, Javier Loricera, Santos Castañeda, Ricardo Blanco

{"title":"Advances in the management of giant cell arteritis-aortitis: biologic therapies and beyond - a narrative review.","authors":"Carmen Secada-Gómez, Adrián Martin-Gutiérrez, Javier Loricera, Santos Castañeda, Ricardo Blanco","doi":"10.1080/14712598.2026.2650104","DOIUrl":"10.1080/14712598.2026.2650104","url":null,"abstract":"Introduction: Giant cell arteritis (GCA) is the most common systemic vasculitis in individuals over 50 years of age. Aortic involvement is frequent, often clinically silent, and significantly increases the risk of thoracic aortic aneurysm, underscoring the need for early detection and optimal management.Areas covered: This review summarizes current knowledge on the pathophysiology, diagnosis, and management of GCA-related aortitis, with emphasis on Th17- and Th1-driven immune pathways and their therapeutic implications. A structured literature search was conducted in major medical databases, including PubMed/MEDLINE, focusing on studies addressing aortic involvement in GCA, imaging modalities for disease assessment, and therapeutic strategies such as glucocorticoids, conventional synthetic disease-modifying antirheumatic drugs, biologic agents, and Janus kinase inhibitors.Expert opinion: Management should follow a treat-to-target strategy aimed at achieving clinical and, when feasible, imaging remission. Although glucocorticoids remain the cornerstone of treatment, steroid-sparing approaches, particularly with tocilizumab, and emerging targeted biotherapies may improve long-term vascular outcomes and prognosis in selected patients.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":"395-405"},"PeriodicalIF":4.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147503593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biologic therapies in Behçet's disease: current evidence, unmet needs, and future directions. behaperet病的生物治疗：目前的证据、未满足的需求和未来的方向。

IF 4 3区医学

Expert Opinion on Biological Therapy Pub Date : 2026-04-01 Epub Date: 2026-03-26 DOI: 10.1080/14712598.2026.2651318

Nikolaos Kougkas

引用次数: 0

Biologic therapies for axial spondyloarthritis: progress and future challenges. c轴的生物治疗：进展和未来的挑战。

IF 4 3区医学

Expert Opinion on Biological Therapy Pub Date : 2026-04-01 DOI: 10.1080/14712598.2026.2653049

Daniel Wendling, Frank Verhœven, Clément Prati

引用次数: 0

Dual clinical remission in severe asthma and chronic rhinosinusitis with nasal polyps: a comparative review of biologic therapies. 重度哮喘和慢性鼻窦炎合并鼻息肉的双重临床缓解：生物治疗的比较回顾。

IF 4 3区医学

Expert Opinion on Biological Therapy Pub Date : 2026-04-01 Epub Date: 2026-03-26 DOI: 10.1080/14712598.2026.2651314

Carlo Lombardi, Francesco Menzella

{"title":"Dual clinical remission in severe asthma and chronic rhinosinusitis with nasal polyps: a comparative review of biologic therapies.","authors":"Carlo Lombardi, Francesco Menzella","doi":"10.1080/14712598.2026.2651314","DOIUrl":"10.1080/14712598.2026.2651314","url":null,"abstract":"Introduction: Severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) are frequent comorbidities driven by common Type 2 inflammatory pathways. While biologics target both conditions, a standardized definition for 'dual clinical remission' is lacking. This review evaluates the comparative efficacy of current biologics to propose a unified treatment strategy.Areas covered: We reviewed pivotal phase 3 and 4 trials (including SINUS-52, SYNAPSE, OSTRO, WAYPOINT, and the head-to-head EVEREST trial) evaluating dupilumab, mepolizumab, benralizumab, omalizumab, and tezepelumab. We analyzed outcomes regarding asthma control, nasal polyp reduction, and olfactory recovery. A new composite definition for dual remission - combining zero exacerbations/oral corticosteroids use with clinically meaningful sinonasal improvement - is proposed.Expert opinion: Achieving dual remission requires a biomarker-guided hierarchy. Dupilumab demonstrates superior efficacy in the 'sinonasal-dominant' phenotype, particularly for olfactory restoration, while anti-IL-5 agents are preferable for the 'exacerbation-dominant' eosinophilic phenotype. Emerging data from the WAYPOINT trial suggests tezepelumab (anti-TSLP) as a potent option for broad epithelial blockade. We advocate moving beyond isolated disease control toward a stratified 'United Airway' remission target guided by fractional exhaled nitric oxide, blood eosinophils, and immunoglobulin E levels.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":"407-414"},"PeriodicalIF":4.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147503539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The patient journey in prurigo nodularis: what lies ahead. 结节性痒疹的病人之旅：前方是什么。

IF 4 3区医学

Expert Opinion on Biological Therapy Pub Date : 2026-04-01 Epub Date: 2026-04-05 DOI: 10.1080/14712598.2026.2654771

Emanuele Scala, Maria-Angeliki Gkini, Nina Magnolo, Alexander Zink, Filomena Russo

引用次数: 0

Therapeutic targeting of PD-1/PD-L1 and CTLA-4 in colorectal cancer: tumor-intrinsic and immune checkpoint signaling. PD-1/PD-L1和CTLA-4在结直肠癌中的靶向治疗：肿瘤内在和免疫检查点信号。

IF 4 3区医学

Expert Opinion on Biological Therapy Pub Date : 2026-04-01 Epub Date: 2026-04-04 DOI: 10.1080/14712598.2026.2655971

Sankha Bhattacharya

{"title":"Therapeutic targeting of PD-1/PD-L1 and CTLA-4 in colorectal cancer: tumor-intrinsic and immune checkpoint signaling.","authors":"Sankha Bhattacharya","doi":"10.1080/14712598.2026.2655971","DOIUrl":"10.1080/14712598.2026.2655971","url":null,"abstract":"Introduction: Colorectal cancer (CRC) employs immune evasion strategies, particularly through the expression of immune checkpoint ligands, including PD-L1. These ligands interact with inhibitory receptors, including programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), which reduces the immune system's antitumor T-cell response. Modulation of these mechanisms has revolutionized the treatment paradigm, particularly for biologically distinct subsets of CRC.Areas covered: This article examines the background and clinical development of immune checkpoint inhibitors (ICIs) in CRC, with particular attention to MSI-H/dMMR tumors with high mutational burden and immunogenicity. It discusses the major trials of nivolumab, pembrolizumab, and ipilimumab, including combinations from the CheckMate-142 and CheckMate-8HW trials. It also mentions new findings on tumor-intrinsic PD-1 signaling, MAPK pathway activation, and chemotherapy resistance. A thorough literature review of key trials and recent peer-reviewed publications provides a perspective on current evidence. PubMed/MEDLINE, Embase, Scopus, and the Cochrane Library (2015-2026) were searched.Expert opinion: The combination of PD-1 and CTLA-4 inhibitors in MSI-H/dMMR metastatic colorectal cancer has demonstrated long-term clinical efficacy and a genuine survival benefit. However, in MSS metastatic colorectal cancer, there has been limited response, emphasizing the importance of innovative combination therapies to address both primary and secondary resistance.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":"387-393"},"PeriodicalIF":4.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147591048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tildrakizumab in the treatment of moderate-to-severe plaque psoriasis: expert insights from Italian real-world experience. Tildrakizumab治疗中重度斑块性银屑病：来自意大利现实世界经验的专家见解

IF 4 3区医学

Expert Opinion on Biological Therapy Pub Date : 2026-03-01 Epub Date: 2026-04-03 DOI: 10.1080/14712598.2026.2641059

Angelo Ruggiero, Martina Burlando, Anna Balato, Alessandra Narcisi, Marco Galluzzo, Luca Mastorino, Eugenia Veronica Di Brizzi, Elena Campione, Luigi Gargiulo, Emanuele Claudio Cozzani, Matteo Megna

{"title":"Tildrakizumab in the treatment of moderate-to-severe plaque psoriasis: expert insights from Italian real-world experience.","authors":"Angelo Ruggiero, Martina Burlando, Anna Balato, Alessandra Narcisi, Marco Galluzzo, Luca Mastorino, Eugenia Veronica Di Brizzi, Elena Campione, Luigi Gargiulo, Emanuele Claudio Cozzani, Matteo Megna","doi":"10.1080/14712598.2026.2641059","DOIUrl":"10.1080/14712598.2026.2641059","url":null,"abstract":"Introduction: Tildrakizumab, a selective interleukin (IL)-23 p19 inhibitor, is an established treatment for moderate-to-severe plaque psoriasis. However, clinical trials are characterized by strict eligibility criteria, which often prevent the recruitment of patients with complex real-world conditions. This review summarizes Italian real-world experience providing critical information for optimizing the use of tildrakizumab in clinical practice, ultimately improving patient outcomes.Areas covered: A literature search was performed in PubMed for real-world studies of tildrakizumab conducted in Italy and published between May 2020 and January 2025. The selected articles reported here provide an overview of the safety and effectiveness of tildrakizumab in real-world in clinically challenging subgroups, including patients with comorbidities, high‑impact area involvement, prior biologic exposure, obesity, and advanced age.Expert opinion: Real‑world evidence from Italy consistently confirms that tildrakizumab provides durable effectiveness and a favorable safety profile across a broad spectrum of patients, often matching or exceeding outcomes reported in pivotal trials. The availability of two approved dosing options may support personalized treatment approaches, although current evidence remains observational and further long-term studies are required to define the full clinical implications.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":"269-283"},"PeriodicalIF":4.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147591056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

When adalimumab fails in childhood chronic uveitis: what comes next? 当阿达木单抗治疗儿童慢性葡萄膜炎失败时：接下来会发生什么？

IF 4 3区医学

Expert Opinion on Biological Therapy Pub Date : 2026-03-01 Epub Date: 2026-03-09 DOI: 10.1080/14712598.2026.2642932

Ilaria Maccora, Gabriele Simonini

引用次数: 0

What does the future hold for antibody-drug conjugate therapies in ovarian cancer? 抗体-药物结合治疗卵巢癌的前景如何？

IF 4 3区医学

Expert Opinion on Biological Therapy Pub Date : 2026-03-01 Epub Date: 2026-03-17 DOI: 10.1080/14712598.2026.2645102

Page C Widick, Ursula A Matulonis, Meghan Shea

引用次数: 0